Novartis May Sell Copy of Amgen’s Neupogen Drug in September

Updated on

Novartis AG’s Sandoz unit may begin selling the first copy of Amgen Inc.’s cancer treatment Neupogen as soon as Sept. 2 after an appeals court ruling Tuesday rejected arguments that it failed to follow regulatory rules.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.